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Background: Serine-threonine inhibitors, such as vemurafenib, are being used increasingly in cancer treatment, and
the toxicity and therapeutic benefit need to be balanced carefully both before and during treatment.
Case presentation: A patient with metastatic melanoma and end stage renal failure who was on peritoneal dialysis
was treated with the serine-threonine kinase inhibitor, vemurafenib. After 5 months of treatment, a substantial
response to vemurafenib was observed using imaging, but when he developed a prolonged QTc interval (common
toxicity criteria (CTC) grade 3), treatment was interrupted. Vemurafenib was restarted at a reduced dose when the
QTc interval returned to normal. The patient has had a significant response to vemurafenib and continued on
treatment for 12 months after beginning the therapy.
Conclusion: This is the first reported case of end stage renal failure in a patient who is taking vemurafenib.
Although the patient developed QTc prolongation, it appears to be asymptomatic, and was managed with dose
reduction. This case highlights the need for closer QTc monitoring at the start and during treatment.
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Metastatic melanoma is a malignancy that is associated
with a poor prognosis and until recently, few treatment
options were available. Vemurafenib (Zelboraf™, Roche
Pharmaceuticals Ltd, Sydney, Australia), is a serine-
threonine kinase BRAF inhibitor that has demonstrated
efficacy in treating metastatic or unresectable metastatic
melanoma that has a known mutation in BRAF protein
[1]. Approximately 40–60% of cutaneous melanomas
carry a BRAF mutation, which is known to enhance cell
proliferation and tumor progression [2]. Vemurafenib
acts as a potent inhibitor of BRAF-mediated cell sig-
naling and proliferation, and has produced improved
progression-free and overall survival in previously un-
treated metastatic melanoma containing BRAF V600E
and V600K mutations. Vemurafenib is highly protein
bound (>99%), and is excreted via feces (94%) and
urine (1%) [3]. While it has been demonstrated that* Correspondence: Mahesh.Iddawela@unimelb.edu.au
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reproduction in any medium, provided the ordrug pharmacokinetics are not significantly altered by
mild to moderate renal dysfunction, there have been
no studies in patients with severe renal dysfunction.
The other important consideration in patients treated
with serine-threonine kinases is the effect that the
renal failure has on cardiac function and serum elec-
trolytes. Here, we report a case of a patient with end
stage renal disease who was treated with vemurafenib
and who developed a prolonged QTc interval during
treatment that was successfully managed using dose
reduction.
Case presentation
A 50-year old male, seen by the surgical team, had a
pigmented lesion on his scalp that had recently in-
creased in size, and become tender and ulcerated. Initial
excision revealed a nodular invasive malignant melan-
oma with a Breslow thickness of 10 mm, 5 mitosis per
square millimeter, and no lymphovascular invasion, and
the excision was deemed incomplete. Following this, he
underwent a wide local excision and sentinel lymph
node biopsy. Because two out of four lymph nodes from
the left supraclavicular fossa had malignant melanomaal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nodes was performed. This showed that 3 out of 29
lymph nodes contained metastatic malignant melanoma
without any extra-nodal spread, and mutation testing
showed the BRAF V600K mutation.
Four years before, the patient had been diagnosed with
chronic renal failure believed to be due to uncontrolled
hypertension. This patient had been on continuous am-
bulatory peritoneal dialysis since the diagnosis, and his
renal function and electrolytes were stable (plasma urea
and creatinine ranged from 20–30 mmol/L and 1004–
1483 umol/L, respectively, potassium was 5.2 mmol/L,
calcium was 2.4 mmol/L, and magnesium was 1.02 mmol/L).
There was no other significant medical history of relevance.
Three months later, a computerized tomography (CT)
scan showed convincing evidence of metastatic disease
with confluent lymphadenopathy in the paratracheal group
of nodes, with the target node measuring 22 mm. There
were also new lymph nodes in the subcarinal region, right
para-oesophageal lymphadenopathy and a right lower lobe
target mass. The lactate dehydrogenase (LDH) level was
also elevated (526 U/L) and the patient was started on
vemurafenib at the recommended dose (960 mg twice
daily).
Four weeks after beginning treatment, his LDH returned
to normal, and the patient denied any significant toxicities.
Results of his serial electrocardiograms (ECGs) were nor-
mal. Importantly, the patient’s renal function remained
stable throughout this time. Four months after beginningFigure 1 Twelve lead ECG showing the prolonged QTc interval (513 mtreatment, there was a reduction in size of the paratracheal
and subcarinal nodes and the pulmonary mass was not
seen. Throughout this time, the patient remained well,
reporting grade 1 photosensitivity as the only side effect of
treatment.
After treatment for 5 months, an ECG demonstrated
that the QTc interval was increased at 511 msec (CTC
grade 3) compared with baseline (467 ms), but it was still
less than the baseline QTc interval of 60 ms (Figures 1
and 2). Vemurafenib treatment was stopped and other
possible causes of the prolonged QTc interval were inves-
tigated. There were no changes in his renal function, elec-
trolyte levels were normal and he was not on any new
medications. A 24-h Halter monitor assessment was car-
ried out to check for the presence of any arrhythmias or
any periods of torsade de pointes, but none were found.
Serial ECGs were carried out, and the QTc returned to the
baseline level over 3 weeks. The patient was re-started on
vemurafenib at a reduced dose (720 mg BD) after discus-
sion with both the renal and cardiology teams. Through-
out treatment, the patient’s renal function remained stable
and there were no significant variations in the electrolytes.
In addition, it was noted that the patient had also had a
high QTc interval (512 msec) 2 years previously, which
resolved spontaneously and no precipitating cause was
found, and there were no other documented episodes of a
prolonged QTc interval.
This patient continued on the reduced dose of vemur-























Figure 2 Change in QTc interval during treatment with
vemurafenib. The QTc interval was normal at baseline and was
high in November 2012. The QTc interval then returned to normal in
December 2012. It also increased above 500 msec in January 2013,
and has since decreased to <500 msec.
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60 ms from baseline, a dose interruption was deemed
unnecessary because he had an increased QTc interval
before starting treatment. An additional ECG a week
later confirmed that the QTc interval was normal and
the fluctuation was not associated with any symptoms.
Staging scans 12 months after re-initiating the treatment
showed that the patient had a partial response according
to RECICT criteria.
This is one of the first reported cases where vemurafenib
was administered to a patient with chronic renal failure
and dialysis. The case demonstrates some important as-
pects about the use of serine-threonine kinase inhibitors
in patients with cancer and other co-morbidities. There is
limited data on vemurafenib in patients with severe renal
impairment, but because hepatic metabolism is the main
route of drug excretion, it is theoretically safe [4]. This
report shows that other factors need to be considered in
this context because electrolyte abnormalities or cardiac
co-morbidities could lead to potential complications.
Management of patients with changes in the QTc
interval is an important issue that needs to be evaluated
because this class of drugs is being increasingly used.
The QTc interval is prolonged in a dose-dependent
manner in response to vemurafenib, and the risk of ma-
lignant arrhythmias such as torsade de pointes can occur
with any increase in QTc interval, even though the risk
is higher at longer intervals [5]. Cardiovascular disease
remains the most common cause of death among patients
with end stage renal failure and cardiac arrhythmias are
an important contributor [6]. One of the major difficulties
in measuring the QTc interval is diurnal variation, and
prolonged QTc intervals are seen in patients with renal
failure for many reasons. The common causes of QTc
changes in patients with renal failure include electrolyte
disturbances, cardiac fibrosis and hypertrophy, changes incellular or interstitial composition during dialysis, and iron
overload. The patient had one episode of prolonged QTc
interval 2 years prior to this reported event. However,
there was no further documented evidence of QTc ab-
normalities and because a prolonged QTc interval is a
potential drug side effect that can have significant con-
sequences, vemurafenib was initially considered to have
caused of the prolongation. However, a detailed adverse
drug reaction analysis using established criteria revealed
that the probability of this being a drug reaction was
low [7]. The patient was started on lower dose as a
precaution.
The risks and benefits need to be carefully assessed on a
case-by-case basis. The decision was made by the team to
continue vemurafenib treatment in this patient because
the patient was responding and the adverse event risk was
low, even though the QTc interval increased to > 500 ms
from <60 ms at baseline.
Conclusions
This case study shows that vemurafenib can be used safely
in patients with chronic renal failure. It also highlights the
importance of regular follow-up including serial ECGs to
prevent treatment complications that result from other
co-morbidities, such as a prolonged QTc interval. It also
demonstrates that such changes may occur after several
months of treatment, and it is important to investigate
all possible causes including those related to other co-
morbidities.
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